Time-kill kinetics of antibiotics active against rapidly growing mycobacteria

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 811-817

  Ferro, Beatriz E ^a   Van Ingen, Jakko ^a   Wattenberg, Melanie ^a   Van Soolingen, Dick ^a,b   Mouton, Johan W ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Emax model; Kill rate; Mycobacterium abscessus; Non tuberculous mycobacteria; Pharmacodynamics

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOXITIN; CLARITHROMYCIN; LINEZOLID; MOXIFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BROTH DILUTION; CONTROLLED STUDY; CURVE FITTING; KINETICS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM FORTUITUM; NONHUMAN; PHARMACODYNAMICS; TIME KILL ASSAY; ATYPICAL MYCOBACTERIUM; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PHYSIOLOGY; STATISTICAL MODEL; TIME;

ANTI-BACTERIAL AGENTS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, STATISTICAL; NONTUBERCULOUS MYCOBACTERIA; TIME FACTORS;

EID: 84924318228     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku431     Document Type: Article

References (17)

1. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement:diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Hoefsloot W, van Ingen J, Andrejak C et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Resp J 2013; 42: 1604-13.
3. van Ingen J, Ferro BE, Hoefsloot Wet al. Drug treatment of pulmonary antituberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther 2013; 11: 1065-77.
4. Magis-Escurra C, Alffenaar JW, Hoefnagels I et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents 2013; 42: 256-61.
5. Clinical Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
6. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355-8.
7. Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics:the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-10.
8. Staneva M, Markova B, Atanasova I et al. Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob Agents Chemother 1994; 38: 981-5.
9. Maurer FP, Bruderer VL, Ritter VL et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014; 58: 3828-36.
10. Bakker-Woudenberg IAJM, van Vianen W, van Soolingen D et al. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. Antimicrob Agents Chemother 2005; 49: 2387-98.
11. de Steenwinkel JEM, de Knegt GJ, ten KateMTet al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 2582-9.
12. Banerjee R, Fernandez MG, Enthaler N et al. Combinations of cefoxitin plus other b-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2013; 32: 827-33.
13. Lerat I, Cambau E, Roth Dit Bettoni R et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis 2014; 209: 905-12.
14. van Ingen J, Egelund EF, Levin A et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012; 186: 559-65.
15. Koh WJ, Jeong BH, Jeon K et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Resp Crit Care Med 2012; 186: 797-802.
16. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011; 95: 761-91.
17. Mouton JW, Theuretzbacher U, Craig WA et al. Tissue concentrations:do we ever learn? J Antimicrob Chemother 2008; 61: 235-7.